Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date |
Reported DateTime |
Company | Symbol | Insider Relationship |
Shares Traded |
Average Price |
Total Amount |
Shares Owned |
Filing |
| 2023-09-14 Sale |
2023-09-18 4:32 pm |
NeuBase Therapeutics Inc. | NBSE | Symetryx Corp 10% Owner |
282,445 | $1.3299 | $375,620 | 0 (Direct) |
View |
| 2023-09-07 Sale |
2023-09-11 5:08 pm |
NeuBase Therapeutics Inc. | NBSE | Symetryx Corp 10% Owner |
207,075 | $1.6261 | $336,731 | 472,926 (Direct) |
View |
| 2023-09-01 Purchase |
2023-09-07 5:19 pm |
NeuBase Therapeutics Inc. | NBSE | Symetryx Corp 10% Owner |
61,076 | $0.978 | $59,732 | 680,081 (Direct) |
View |
| 2022-03-30 Purchase |
2022-04-01 4:16 pm |
NeuBase Therapeutics Inc. | NBSE | Mann William Roland Chief Operating Officer |
6,200 | $1.92 | $11,904 | 11,200 (Direct) |
View |
| 2022-03-18 Purchase |
2022-03-21 4:06 pm |
NeuBase Therapeutics Inc. | NBSE | Branning Todd P. Chief Financial Officer |
10,000 | $1.81 | $18,100 | 30,000 (Direct) |
View |
| 2022-03-16 Purchase |
2022-03-18 4:11 pm |
NeuBase Therapeutics Inc. | NBSE | Branning Todd P. Chief Financial Officer |
20,000 | $1.68 | $33,600 | 20,000 (Direct) |
View |
| 2022-03-01 Purchase |
2022-03-07 7:13 pm |
NeuBase Therapeutics Inc. | NBSE | RICHMAN ERIC I Director |
3,880 | $1.6372 | $6,352 | 72,707 (Indirect Direct) |
View |
| 2021-06-18 Purchase |
2021-06-21 11:03 am |
NeuBase Therapeutics Inc. | NBSE | GOLDSTEIN DOV A MD Director |
8,000 | $4.75 | $38,000 | 30,000 (Direct) |
View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date |
Reported DateTime |
Exercisable Expiration |
Company | Symnbol | Insider Relationship |
Shares Traded |
Conversion Price |
Shares Owned |
Filing |
| 2023-09-18 Ownership |
2023-09-20 8:42 pm |
N/A N/A |
NeuBase Therapeutics Inc. | NBSE | Symetryx Corp Shiff Aleta Shiff Barry no longer 10% Owner |
0 | $0 | 192,481 (Direct) |
View |
Ownership(A) |
2023-09-12 5:20 pm |
N/A N/A |
NeuBase Therapeutics Inc. | NBSE | Symetryx Corp Shiff Barry Shiff Aleta 10% Owner |
0 | $0 | 190,481 (Direct) |
View |
Ownership |
2023-09-01 2:51 pm |
N/A N/A |
NeuBase Therapeutics Inc. | NBSE | Symetryx Corp 10% Owner |
0 | $0 | 618,925 (Direct) |
View |
| 2023-08-02 Exercise |
2023-08-04 4:39 pm |
N/A N/A |
NeuBase Therapeutics Inc. | NBSE | Stephan Dietrich A Founder and CEO 10% Owner |
93,234 | $0.022 | 238,162 (Direct) |
View |
| 2023-08-02 Exercise |
2023-08-04 4:39 pm |
2019-07-12 2023-12-31 |
NeuBase Therapeutics Inc. | NBSE | Stephan Dietrich A Founder and CEO 10% Owner |
93,234 | $0 | 238,162 (Direct) |
View |
| 2023-03-16 Option Award |
2023-03-17 4:11 pm |
N/A N/A |
NeuBase Therapeutics Inc. | NBSE | Branning Todd P. Chief Financial Officer |
54,200 | $0 | 84,200 (Direct) |
View |
| 2023-03-16 Option Award |
2023-03-17 4:11 pm |
N/A N/A |
NeuBase Therapeutics Inc. | NBSE | Stephan Dietrich A CEO and Director 10% Owner |
153,000 | $0 | 2,898,594 (Direct) |
View |
| 2023-02-13 Exercise |
2023-02-15 7:30 pm |
2019-07-12 2023-12-31 |
NeuBase Therapeutics Inc. | NBSE | Stephan Dietrich A President and CEO 10% Owner |
655,000 | $0 | 4,610,274 (Direct) |
View |
| 2022-11-03 Option Award |
2022-11-04 5:00 pm |
N/A 2032-11-03 |
NeuBase Therapeutics Inc. | NBSE | Branning Todd P. Chief Financial Officer |
200,000 | $0 | 200,000 (Direct) |
View |
| 2022-09-28 Exercise |
2022-09-30 7:45 pm |
2019-07-12 2023-12-31 |
NeuBase Therapeutics Inc. | NBSE | Stephan Dietrich A CEO 10% Owner |
750,000 | $0.0011 | 4,610,274 (Direct) |
View |
| 2022-09-09 Option Award |
2022-09-12 5:01 pm |
N/A 2032-09-09 |
NeuBase Therapeutics Inc. | NBSE | RICHMAN ERIC I Director |
37,600 | $0 | 37,600 (Direct) |
View |
| 2022-09-09 Option Award |
2022-09-12 5:01 pm |
N/A 2032-09-09 |
NeuBase Therapeutics Inc. | NBSE | PRENDERGAST FRANKLYN G Director |
37,600 | $0 | 37,600 (Direct) |
View |
| 2022-09-09 Option Award |
2022-09-12 5:01 pm |
N/A 2032-09-09 |
NeuBase Therapeutics Inc. | NBSE | McDougall Gerald J Director |
37,600 | $0 | 37,600 (Direct) |
View |
| 2022-09-09 Option Award |
2022-09-12 5:00 pm |
N/A 2032-09-09 |
NeuBase Therapeutics Inc. | NBSE | GOLDSTEIN DOV A MD Director |
37,600 | $0 | 37,600 (Direct) |
View |
| 2022-09-09 Option Award |
2022-09-12 5:00 pm |
N/A 2032-09-09 |
NeuBase Therapeutics Inc. | NBSE | Ende Eric J Director |
37,600 | $0 | 37,600 (Direct) |
View |
| 2022-01-24 Option Award |
2022-01-25 2:03 pm |
N/A 2032-01-24 |
NeuBase Therapeutics Inc. | NBSE | Mann William Roland Chief Operating Officer |
60,180 | $0 | 60,180 (Direct) |
View |
| 2022-01-24 Option Award |
2022-01-25 2:00 pm |
N/A 2032-01-24 |
NeuBase Therapeutics Inc. | NBSE | Rojas-Caro Sandra Chief Medical Officer |
44,592 | $0 | 44,592 (Direct) |
View |
| 2022-01-24 Option Award |
2022-01-25 1:50 pm |
N/A 2032-01-24 |
NeuBase Therapeutics Inc. | NBSE | Stephan Dietrich A President and CEO 10% Owner |
306,000 | $0 | 306,000 (Direct) |
View |
| 2022-01-10 Option Award |
2022-01-10 7:19 pm |
N/A 2032-01-10 |
NeuBase Therapeutics Inc. | NBSE | Branning Todd P. Chief Financial Officer |
300,000 | $0 | 300,000 (Direct) |
View |
| 2021-12-31 Exercise |
2022-01-05 9:45 pm |
2019-07-12 2028-12-31 |
NeuBase Therapeutics Inc. | NBSE | Stephan Dietrich A President and CEO 10% Owner |
42,250 | $0.001 | 4,610,274 (Direct) |
View |
| 2022-01-01 Option Award |
2022-01-05 4:05 pm |
N/A 2032-01-01 |
NeuBase Therapeutics Inc. | NBSE | Ende Eric J Director |
165,803 | $0 | 165,803 (Direct) |
View |
| 2021-08-16 Option Award |
2021-09-24 5:03 pm |
N/A 2031-08-16 |
NeuBase Therapeutics Inc. | NBSE | Mann William Roland COO |
25,000 | $0 | 25,000 (Direct) |
View |
| 2021-08-19 Option Award |
2021-09-17 4:17 pm |
N/A 2031-08-19 |
NeuBase Therapeutics Inc. | NBSE | McDougall Gerald J Director |
38,135 | $0 | 38,135 (Direct) |
View |
| 2021-08-19 Option Award |
2021-09-17 4:17 pm |
N/A 2031-08-19 |
NeuBase Therapeutics Inc. | NBSE | GOLDSTEIN DOV A MD Director |
38,135 | $0 | 38,135 (Direct) |
View |
| 2021-08-19 Option Award |
2021-09-17 4:17 pm |
N/A 2031-08-19 |
NeuBase Therapeutics Inc. | NBSE | PRENDERGAST FRANKLYN G Director |
38,135 | $0 | 38,135 (Direct) |
View |
| 2021-08-19 Option Award |
2021-09-17 4:16 pm |
N/A 2031-08-19 |
NeuBase Therapeutics Inc. | NBSE | RICHMAN ERIC I Director |
38,135 | $0 | 38,135 (Direct) |
View |
| 2021-05-24 Option Award |
2021-05-25 4:13 pm |
N/A 2031-05-24 |
NeuBase Therapeutics Inc. | NBSE | Rojas-Caro Sandra Chief Medical Officer |
280,000 | $0 | 280,000 (Direct) |
View |
| 2021-05-24 Option Award |
2021-05-25 4:12 pm |
N/A 2031-05-24 |
NeuBase Therapeutics Inc. | NBSE | Motesharei Kianoush See Remarks |
250,000 | $0 | 250,000 (Direct) |
View |
| 2021-05-11 Option Award |
2021-05-13 6:03 pm |
N/A 2031-05-11 |
NeuBase Therapeutics Inc. | NBSE | McDougall Gerald J Director |
92,219 | $0 | 92,219 (Direct) |
View |